• 1
    Doak PB, Montgomerie JZ, North JD, Smith F. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br Med J 1968; 4: 746.
  • 2
    Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583.
  • 3
    Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006; 19: 259.
  • 4
    Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005; 80: 1692.
  • 5
    Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901.
  • 6
    Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053.
  • 7
    Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 8.
  • 8
    Nalesnik MA. The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach. Transpl Infect Dis 2001; 3: 88.
  • 9
    Tanner JE, Alfieri C. The Epstein–Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001; 3: 60.
  • 10
    Rubin RH. Infection in the organ transplant recipient. In: RubinRH, YoungLS, eds. Clinical Approach to Infection in the Compromised Host. New York: Kluwer Academic/Plenum, 2002: 573679.
  • 11
    Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein–Barr virus: a distinct entity? J Clin Oncol 1998; 16: 2052.
  • 12
    Dotti G, Fiocchi R, Motta T, et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 2002; 74: 1095.
  • 13
    Ghobrial IM, Habermann TM, Macon WR, Ristow KM, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 2005; 79: 244.
  • 14
    Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222.
  • 15
    Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514.
  • 16
    Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233.
  • 17
    Bakker NA, Van Imhoff GW, Verschuuren EA, et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005; 19: 327.
  • 18
    Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005; 23: 7574.
  • 19
    Beynet DP, Wee SA, Horwitz SS, et al. Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. Arch Dermatol 2004; 140: 1140.
  • 20
    Phan TG, O'Neill BP, Kurtin PJ. Posttransplant primary CNS lymphoma. Neuro-oncol 2000; 2: 229.
  • 21
    Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein–Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165.
  • 22
    Baldanti F, Grossi P, Furione M, et al. High levels of Epstein–Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 2000; 38: 613.
  • 23
    Stevens SJ, Verschuuren EA, Verkuujlen SA, Van Den Brule AJ, Meijer CJ, Middeldorp JM. Role of Epstein–Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma 2002; 43: 831.
  • 24
    Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569.
  • 25
    Howard TK, Klintmalm GB, Stone MJ, et al. Lymphoproliferative disorder masquerading as rejection in liver transplant recipients – an early aggressive tumor with atypical presentation. Transplantation 1992; 53: 1145.
  • 26
    Trpkov K, Marcussen N, Rayner D, Lam G, Solez K. Kidney allograft with a lymphocytic infiltrate: acute rejection, posttransplantation lymphoproliferative disorder, neither, or both entities? Am J Kidney Dis 1997; 30: 449.
  • 27
    Paya CV, Fung JJ, Nalesnik MA, et al. Epstein–Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and the Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517.
  • 28
    Gattuso P, Reddy VB, Kizilbash N, Kluskens L, Selvaggi SM. Role of fine-needle aspiration in the clinical management of solid organ transplant recipients: a review. Cancer 1999; 87: 286.
  • 29
    Frizzera G, Hanto DW, Gajl-Peczalska KJ, Rosai J, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262.
  • 30
    Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552.
  • 31
    Yin CC, Medeiros LJ, Abruzzo LV, Jones D, Farhood AI, Thomazy VA. EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient. Am J Clin Pathol 2005; 123: 222.
  • 32
    Dotti G, Fiocchi R, Motta T, et al. Epstein–Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000; 69: 827.
  • 33
    Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87.
  • 34
    Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723.
  • 35
    Duvoux C, Pageaux GP, Vanlemmens C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002; 74: 1103.
  • 36
    Pirsch JD. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. Transplantation 1999; 68: 1203.
  • 37
    Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002; 6: 396.
  • 38
    Dharnidharka VR. Post-transplant lymphoproliferative disease: association with induction therapy? Drugs 2006; 66: 429.
  • 39
    Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66: 493.
  • 40
    Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76: 984.
  • 41
    Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80: 749.
  • 42
    Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710.
  • 43
    Dierksheide JE, Baiocchi RA, Ferketich AK, et al. IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. Blood 2005; 105: 1558.
  • 44
    Lee TC, Savoldo B, Barshes NR, et al. Use of cytokine polymorphisms and Epstein–Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant 2006; 20: 389.
  • 45
    Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877.
  • 46
    Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein–Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14: 214.
  • 47
    Shahinian VB, Muirhead N, Jevnikar AM, et al. Epstein–Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation 2003; 75: 851.
  • 48
    Khanna R, Moss DJ, Burrows SR. Vaccine strategies against Epstein–Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999; 170: 49.
  • 49
    Duraiswamy J, Sherritt M, Thomson S, et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003; 101: 3150.
  • 50
    Babel N, Gabdrakhmanova L, Hammer M, et al. Induction of pre-transplant Epstein–Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases. Transpl Infect Dis 2005; 7: 133.
  • 51
    Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894.
  • 52
    Humar A, Hebert D, Davies HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein–Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006; 81: 856.
  • 53
    Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6: 1906.
  • 54
    Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346.
  • 55
    Manez R, Breinig MK, Linden P, et al. Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein–Barr virus (EBV)-seronegative adult liver transplant recipients. Transpl Int 1994; 7: S235.
  • 56
    Manez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein–Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462.
  • 57
    Bakker NA, Van Imhoff GW, Verschuuren EA, et al. HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation 2005; 80: 595.
  • 58
    Gao SZ, Chaparro SV, Perlroth M, et al. Post-transplantation lymphoproliferative disease in heart and heart–lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003; 22: 505.
  • 59
    Wong JY, Tait B, Levvey B, et al. Epstein–Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease. Transplantation 2004; 78: 205.
  • 60
    Bouwes BJN, Vermeer BJ, Van Der Woude FJ, et al. Relation between skin cancer and HLA antigens in renal-transplant recipients. N Engl J Med 1991; 325: 843.
  • 61
    Kroes AC, Van Der Pijl JW, Van Tol MJ, et al. Rapid occurrence of lymphoproliferative disease after pancreas–kidney transplantation performed during acute primary Epstein–Barr virus infection. Clin Infect Dis 1997; 24: 339.
  • 62
    Paranjothi S, Yusen RD, Kraus MD, Lynch JP, Patterson GA, Trulock EP. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant 2001; 20: 1054.
  • 63
    Kew CE, Lopez-Ben R, Smith JK, et al. Posttransplant lymphoproliferative disorder localized near the allograft in renal transplantation. Transplantation 2000; 69: 809.
  • 64
    Godyn JJ, Hicks DG, Hsu SH, et al. Demonstration of passenger leukocytes in a case of Epstein–Barr virus posttransplant lymphoproliferative disorder using restriction fragment length polymorphism analysis. Arch Pathol Lab Med 1992; 116: 249.
  • 65
    Petit B, Le Meur Y, Jaccard A, et al. Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. Transplantation 2002; 73: 265.
  • 66
    Caillard S, Pencreach E, Braun L, et al. Simultaneous development of lymphoma in recipients of renal transplants from a single donor: donor origin confirmed by human leukocyte antigen staining and microsatellite analysis. Transplantation 2005; 79: 79.
  • 67
    Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103: 748.
  • 68
    Chadburn A, Suciu-Foca N, Cesarman E, Reed E, Michler RE, Knowles DM. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol 1995; 147: 1862.
  • 69
    Gulley ML, Swinnen LJ, Plaisance KT Jr, Schnell C, Grogan TM, Schneider BG. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 2003; 76: 959.
  • 70
    Wood BL, Sabath D, Broudy VC, Raghu G. The recipient origin of posttransplant lymphoproliferative disorders in pulmonary transplant patients. A report of three cases. Cancer 1996; 78: 2223.
  • 71
    Peterson MR, Emery SC, Yung GL, Masliah E, Yi ES. Epstein–Barr virus-associated posttransplantation lymphoproliferative disorder following lung transplantation is more commonly of host origin. Arch Pathol Lab Med 2006; 130: 176.
  • 72
    Birkeland SA. Chronic antigenic stimulation from the graft as a possible oncogenic factor after renal transplant. Scand J Urol Nephrol 1983; 17: 355.
  • 73
    Cosio FG, Nuovo M, Delgado L, et al. EBV kidney allograft infection: possible relationship with a peri-graft localization of PTLD. Am J Transplant 2004; 4: 116.
  • 74
    Becker JL, Miller F, Nuovo GJ, Josepovitz C, Schubach WH, Nord EP. Epstein–Barr virus infection of renal proximal tubule cells: possible role in chronic interstitial nephritis. J Clin Invest 1999; 104: 1673.
  • 75
    Comoli P, Binggeli S, Ginevri F, Hirsch HH. Polyomavirus-associated nephropathy: update on BK virus-specific immunity. Transpl Infect Dis 2006; 8: 86.
  • 76
    Bates WD, Gray DW, Dada MA, et al. Lymphoproliferative disorders in Oxford renal transplant recipients. J Clin Pathol 2003; 56: 439.
  • 77
    Doria C, Marino IR, Scott VL, et al. Posttransplant lymphoproliferative disorders presenting at sites of previous surgical intervention. Transplantation 2003; 75: 1066.
  • 78
    Herrmann BW, Sweet SC, Molter DW. Sinonasal posttransplant lymphoproliferative disorder in pediatric lung transplant patients. Otolaryngol Head Neck Surg 2005; 133: 38.
  • 79
    Claudon M, Kessler M, Champigneulle J, Lefevre F, Hestin D, Renoult E. Lymphoproliferative disorders after renal transplantation: role of medical imaging. Eur Radiol 1998; 8: 1686.
  • 80
    Rappaport DC, Chamberlain DW, Shepherd FA, Hutcheon MA. Lymphoproliferative disorders after lung transplantation: imaging features. Radiology 1998; 206: 519.
  • 81
    Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124: 1242.
  • 82
    Douglas RS, Goldstein SM, Katowitz JA, et al. Orbital presentation of posttransplantation lymphoproliferative disorder: a small case series. Ophthalmology 2002; 109: 2351.
  • 83
    Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein–Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2715.
  • 84
    Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein–Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84: 972.
  • 85
    McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604.
  • 86
    Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 2222.
  • 87
    Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein–Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999; 37: 132.
  • 88
    Niesters HG, Van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein–Barr virus. J Clin Microbiol 2000; 38: 712.
  • 89
    Wagner HJ, Jabs W, Smets F, et al. Real-time polymerase chain reaction (RQ-PCR) for the monitoring of Epstein–Barr virus (EBV) load in peripheral blood mononuclear cells. Klin Padiatr 2000; 212: 206.
  • 90
    Jabs WJ, Hennig H, Kittel M, et al. Normalized quantification by real-time PCR of Epstein–Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol 2001; 39: 564.
  • 91
    Stevens SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein–Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001; 39: 1211.
  • 92
    Fafi-Kremer S, Brengel-Pesce K, Bargues G, et al. Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein–Barr virus load in whole blood, peripheral mononuclear cells and plasma. J Clin Virol 2004; 30: 157.
  • 93
    Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein–Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001; 72: 1012.
  • 94
    Wagner HJ, Fischer L, Jabs WJ, Holbe M, Pethig K, Bucsky P. Longitudinal analysis of Epstein–Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 2002; 74: 656.
  • 95
    Limaye AP, Huang ML, Atienza EE, Ferrenberg JM, Corey L. Detection of Epstein–Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. J Clin Microbiol 1999; 37: 1113.
  • 96
    Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein–Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001; 3: 79.
  • 97
    Tsai DE, Nearey M, Hardy CL, et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant 2002; 2: 946.
  • 98
    Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979.
  • 99
    Axelrod DA, Holmes R, Thomas SE, Magee JC. Limitations of EBV – PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder. Pediatr Transplant 2003; 7: 223.
  • 100
    Leung E, Shenton BK, Green K, et al. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler. Transpl Infect Dis 2004; 6: 156.
  • 101
    Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTL). Blood 2006; 108: 2942.
  • 102
    Smets F, Sokal EM. Epstein–Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant 2002; 6: 280.
  • 103
    Lee TC, Goss JA, Rooney CM, et al. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transpl 2006; 20: 389.
  • 104
    Smets F, Latinne D, Bazin H, et al. Ratio between Epstein–Barr viral load and anti-Epstein–Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002; 73: 1603.
  • 105
    Birkeland SA, Bendtzen K, Moller B, Hamilton-Dutoit S, Andersen HK. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 1999; 67: 876.
  • 106
    Muti G, Klersy C, Baldanti F, et al. Epstein–Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Br J Haematol 2003; 122: 927.
  • 107
    Baiocchi OC, Colleoni GW, Caballero OL, et al. Epstein–Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case–control study in a renal transplant cohort. Leuk Lymphoma 2005; 46: 533.
  • 108
    Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol 1997; 158: 4045.
  • 109
    Russ PD, Way DE, Pretorius DH, Manco-Johnson ML, Weil R III. Posttransplant lymphoma. Sonographic characteristics of renal allograft involvement. J Ultrasound Med 1987; 6: 453.
  • 110
    Pickhardt PJ, Wippold FJ. Neuroimaging in posttransplantation lymphoproliferative disorder. AJR Am J Roentgenol 1999; 172: 1117.
  • 111
    O'Connor JA, Cogley C, Burton M, Lancaster-Weiss K, Cordle RA. Posttransplantation lymphoproliferative disorder: endoscopic findings. J Pediatr Gastroenterol Nutr 2000; 31: 458.
  • 112
    Scarsbrook AF, Warakaulle DR, Dattani M, Traill Z. Post-transplantation lymphoproliferative disorder: the spectrum of imaging appearances. Clin Radiol 2005; 60: 47.
  • 113
    Pickhardt PJ, Siegel MJ. Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology 1999; 213: 73.
  • 114
    Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206: 475.
  • 115
    Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006; 91: 522.
  • 116
    Marom EM, McAdams HP, Butnor KJ, Coleman RE. Positron emission tomography with fluoro-2-deoxy-d-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. J Thorac Imaging 2004; 19: 74.
  • 117
    O'Conner AR, Franc BL. FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation. Nucl Med Commun 2005; 26: 1107.
  • 118
    Bakker NA, Pruim J, De Graaf W, Van Son WJ, Van der Jagt EJ, Van Imhoff GW. PTLD visualization by FDG-PET: improved detection of extranodal localizations. Am J Transplant 2006; 6: 1984.